ReviewFrontiers in immunology2017
Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases.
Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review.Nutrients · 2023Pooled it
- Genetically Modified Lactic Acid Bacteria: a Promising Mucosal Delivery Vector for Vaccines.Probiotics and antimicrobial proteins · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- The Degree of Mucosa-Associated Microecological Imbalance in Ulcerative Colitis Patients with Different Mayo Score and Its Relationship with Mucosal Mechanical Barrier Damage.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Optimization of growth conditions and the inducer concentration for increasing spike protein expression in recombinantBioscience of microbiota, food and health · 2025Article
- Genetically engineered bacteria as inflammatory bowel disease therapeutics.Engineering microbiology · 2024Review
- Importance of Probiotics in Fish Aquaculture: Towards the Identification and Design of Novel Probiotics.Microorganisms · 2024Review
- Development of a Single-Chain Fragment Variable that Binds to the SARS-CoV-2 Spike Protein Produced by Genetically Modified Lactic Acid Bacteria.Molecular biotechnology · 2024Article
- Development of fluorescence-labeled antibody for immune checkpoint inhibitor using engineered probiotics.AMB Express · 2023Article
- Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection.Journal of human hypertension · 2022Review
- Natural compounds as safe therapeutic options for ulcerative colitis.Inflammopharmacology · 2022Review
- Leveraging diet to engineer the gut microbiome.Nature reviews. Gastroenterology & hepatology · 2021Review
- Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa.Bioengineered · 2021Article
- Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo.Molecular systems biology · 2021Article
- Mechanisms of Candida Resistance to Antimycotics and Promising Ways to Overcome It: The Role of Probiotics.Probiotics and antimicrobial proteins · 2021Review
- Angiotensin (1-7) Expressing Probiotic as a Potential Treatment for Dementia.Frontiers in aging · 2021Article
- Construction of Genetically Modified Lactococcus lactis Producing Anti-human-CTLA-4 Single-Chain Fragment Variable.Molecular biotechnology · 2020Article
- Engineered IL-10 variants elicit potent immunomodulatory effects at low ligand doses.Science signaling · 2020Article
- Construction of genetically modified Lactococcus lactis that produces bioactive anti-interleukin-4 single-chain fragment variable.Molecular biology reports · 2020Article
- Biology and therapeutic potential of interleukin-10.The Journal of experimental medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn's disease, are chronic inflammatory diseases characterized by dysregulated immune responses of the gastrointestinal tract. In recent years, the incidence of IBDs has increased in developed nations, but their prophylaxis/treatment is not yet established. Site-directed delivery of molecules showing anti-inflammatory properties using genetically modified (gm)-probiotics shows promise as a new strategy for the prevention and treatment of IBD. Advantages of gm-probiotics include (1) the ability to use bacteria as a delivery vehicle, enabling safe and long-term use by humans, (2) decreased risks of side effects, and (3) reduced costs. The intestinal delivery of anti-inflammatory proteins such as cytokines and enzymes using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.